ClinicalTrials.gg
CompletedNCT00330317Updated Feb 7, 2017

Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer

A Phase 3 interventional study of letrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in United Kingdom. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
36th of 159
300 · median 95
Started
2006
with 6 others
Phase 3
41 of 162
4 open now
Registered
35th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 36th largest by enrollment of the 159 interventional ones that give a count, is one of 7 that started in 2006, is one of 41 in phase 3, and was the 35th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

The aim of this study is to assess the safety and efficacy of neoadjuvant hormone therapy with letrozole in postmenopausal women with estrogen- and/or progesterone-receptor positive primary breast cancer on tumour regression to permit breast conserving surgery.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Letrozole
  • Breast Conserving Surgery
  • NeoAdjuvant
  • Early Breast Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women able to comply with the protocol requirements with confirmed primary invasive breast cancer whose tumours are estrogen-and/or progesterone-receptor positive
  2. Clinical stage T2 or >T2 tumours which in the investigators' opinion would not be eligible for breast-conserving surgery. The nodal status will be evaluated by palpation and/or ultrasound.
  3. Postmenopausal status defined by one of the following:

    • Women with an intact uterus AND

      • ≥ 55 years of age, OR
      • \< 55 years of age without menses for the last 5 years, OR
      • \< 55 years of age and have not had menses for at least the last 12 months (but have had menses in the last 5 years) and have postmenopausal levels of follicle-stimulating hormone.
    • Women without an intact uterus AND

      • ≥ 55 years of age, OR
      • \< 55 years of age and postmenopausal levels of follicle-stimulating hormone
    • Both ovaries removed (prior to the diagnosis of breast cancer).
  4. Tumour measurable by clinical examination, mammography and ultrasound
  5. Adequate bone marrow function as shown by:

    • WBC ≥ 3.5 x 10\^9/L
    • ≥ 1.5 x 10\^9/L
    • ≥ LLN
    • > 10 g/dL

Exclusion criteria

Exclusion Criteria:

  1. Multifocal disease (cancer that starts in several different sites)
  2. Patients with bilateral breast tumours.
  3. Patients who are eligible for breast conserving surgery.
  4. Evidence of inflammatory breast cancer or distant .
  5. Simultaneous anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy (including ), bisphosphonate therapy and radiotherapy. NOTE: Bisphosphonate therapy for osteoporosis is NOT excluded, and can be continued. Patients who have received hormone replacement therapy will NOT be excluded if it is discontinued at least 2 weeks before starting the study.

The following additional treatments are NOT allowed during the treatment phase of the study:

  • Any other anti-cancer therapy
  • Hormone replacement therapy.
  • Estrogen cream (including any intra-vaginal preparation).
  • Steroids other than creams or inhalers.
  • Megestrol acetate for the treatment of hot flushes.
  • Radiation therapy.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Letrozole

    Drug: letrozole

Interventions

  • 2.5mg letrozole once-daily

    Also known as: Femara, FEM345

06

What researchers measure

Primary outcomes

  1. Optimum length of treatment with letrozole (2.5 mg daily) preoperatively, on tumour measured by clinical examination and breast ultrasound

    Time frame: 12 months

Secondary outcomes

  1. Reduction in tumour volume every 2 months throughout the study

    Time frame: 12 months

  2. Response rate in line with the Response Evaluation Criteria in Solid Tumors criteria

    Time frame: 12 months

  3. Long term (5-year) local recurrence rate

    Time frame: 5 years

  4. Safety and tolerability of the treatment prior to surgery

    Time frame: 5 years

07

Study locations

20 sites
  • Novartis Investigative Site
    Bournemouth, United Kingdom
  • Novartis Investigative Site
    Brighton, United Kingdom
  • Novartis Investigative Site
    Bristol, United Kingdom
  • Novartis Investigative Site
    Crewe, United Kingdom
  • Novartis Investigative Site
    Dundee, United Kingdom
  • Novartis Investigative Site
    East Sussex, United Kingdom
  • Novartis Investigative Site
    Epping, United Kingdom
  • Novartis Investigative Site
    Farnworth, United Kingdom
  • Novartis Investigative Site
    Gateshead, United Kingdom
  • Novartis Investigative Site
    Glasgow, United Kingdom
  • Novartis Investigative Site
    Hants, United Kingdom
  • Novartis Investigative Site
    Leicester, United Kingdom
  • Novartis Investigative Site
    Liverpool, United Kingdom
  • Novartis Investigative Site
    London, United Kingdom
  • Novartis Investigative Site
    Luton, United Kingdom
  • Novartis Investigative Site
    Manchester, United Kingdom
  • Novartis Investigative Site
    Newcastle, United Kingdom
  • Novartis Investigative Site
    Poole, United Kingdom
  • Novartis Investigative Site
    St. Leonards on Sea, United Kingdom
  • Novartis Investigative Site
    West Smithfield, United Kingdom
08

References and documents

Publications

  • Carpenter R, Doughty JC, Cordiner C, Moss N, Gandhi A, Wilson C, Andrews C, Ellis G, Gui G, Skene AI. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 2014 Apr;144(3):569-76. doi: 10.1007/s10549-014-2835-8. Epub 2014 Feb 23. PubMed 24562823 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Mar 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2006
First posted
May 26, 2006
Start
Feb 2006
Primary completionActual
Mar 2010
CompletionActual
Nov 16, 2010
Last update
Feb 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00330317
Responsible party
Sponsor
First posted
May 26, 2006
Start date
Feb 2006
Primary completion
Mar 2010
Completion
Nov 16, 2010
Last update
Feb 7, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmeceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion